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Little is known about the dynamics of human papillomavirus (HPV) infection and subsequent development of high-grade cervical
intraepithelial neoplasia (CIN2/3), particularly in women 430 years of age. This information is needed to assess the impact of HPV
vaccines and consider new screening strategies. A cohort of 1728 women 15–85 years old with normal cytology at baseline was
followed every 6 months for an average of 9 years. Women with squamous intraepithelial lesions were referred for biopsy and
treatment. The Kaplan–Meier method was used to estimate the median duration of infection and Cox regression analysis was
undertaken to assess determinants of clearance and risk of CIN2/3 associated with HPV persistence. No difference in the likelihood
of clearance was observed by HPV type or woman’s age, with the exception of lower clearance for HPV16 infection in women under
30 years of age. Viral load was inversely associated with clearance. In conclusion, viral load is the main determinant of persistence, and
persistence of HPV16 infections carry a higher risk of CIN2/3.
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Cervical human papillomavirus (HPV) infection is the necessary,
but not a sufficient, cause of cervical cancer (Walboomers et al,
1999; Mun ˜oz et al, 2003). Only a small fraction of those with
persistent HPV infections develop cervical cancer and its
immediate precursors (Schiffman and Kjaer, 2003). Although
persistent HPV infection has been considered a prerequisite for
cervical cancer (Bosch et al, 2008), there is no consensus on its
definition. Most investigators define it as detection of the same
HPV type or group of types on two consecutive visits, but these
could be from 4 months up to 5–7 years apart (Schiffman and
Kjaer, 2003; Castle et al, 2005). A recent review of problems with
this approach suggests restricting analyses to incident infections,
and considering the duration of the infection rather than the
number of positive tests (Woodman et al, 2007). Agreement on
definition will facilitate comparisons of results from studies, on
end points in vaccine trials and screening policy recommenda-
tions. Some recent reports cast doubts on the need for persistence
for progression to high-grade squamous intraepithelial lesions
(HSIL) or intraepithelial neoplasia (CIN2/3) (Schiffman et al, 2005;
Winer et al, 2005). Moreover, most cohort studies of cervical HPV
infections have been in young women (Ho et al, 1998; Moscicki
et al, 2001; Woodman et al, 2001; Brown et al, 2005; Winer et al,
2005), one suggesting that HSIL is often an early manifestation of
HPV infection in young women (Winer et al, 2005). We present
results on clearance of HPV incident infection and its determi-
nants and estimate the risk of progression to CIN2/3 in a cohort of
young and older Colombian women followed at regular scheduled
visits. We propose a new definition of persistence based on
duration of infection, and compare it with the traditional
definition based on detection of HPV DNA in two consecutive
visits.
MATERIALS AND METHODS
Between November 1993 and November 1995, the National Cancer
Institute of Colombia (INC) invited 2200 women aged 15–85 years
to participate in a prospective study (Molano et al, 2002a),
previously approved by the INC ethics committee. All study
participants signed an informed consent form in compliance with
the clinical research guidelines. The 2200 women were randomly
selected from four low-income health districts of Bogota ´ who had
consulted cervical cancer screening centres or family planning
clinics. Methods of recruitment and data collection have been
described elsewhere (Molano et al, 2002a,b). Briefly, eligible
women were those residing in Bogota ´, without history of cervical
neoplasia, conisation or hysterectomy, willing to participate and
who signed an informed consent form. At study entry, participants
responded to a questionnaire on risk factors for cervical cancer
and underwent a pelvic examination with collection of cervical
cells for cytology and HPV detection. Follow-up visits were
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yscheduled every 6 months until March 2004. At each visit, a
questionnaire on lifestyle and sexual behaviour was used, a pelvic
examination was performed and cervical specimens were collected
using Ayre spatulas and endocervical brushes for cytology and
HPV detection. The specimens were eluted in phosphate-buffered
saline þ0.05% thiomersal. Colposcopic examination was per-
formed in all women with repeated diagnosis of low-grade
squamous intraepithelial lesions (LSIL) or with cytological
evidence of HSIL. Colposcopically guided cervical biopsies were
performed in women with cytological or colposcopic evidence of
HSIL.
From the 2200 women invited to participate, 53 (2.4%) refused
and 8 (0.4%) were ineligible (due to mental illness, hysterectomy
or history of cervical cancer) leaving 2139 women. For this
analysis, we only included women with normal Pap smear results
and a valid HPV DNA sample at baseline with at least two visits
during follow-up. If DNA results were not available for the first
visit (because no scrape was available or due to failure to amplify
the b-globin gene), the second visit was used as baseline.
Human papillomavirus presence and type was assessed by
Southern blot hybridisation of GP5þ/bioGP6þ PCR products
using a general probe of specific DNA fragments from cloned
DNA of six HPV types, and by the GP5þ/GP6þ PCR enzyme
immunoassay (PCR-EIA) as previously described (Jacobs et al,
1997; Molano et al, 2002a). For the EIA, HPV-positive samples
were first subjected to a group-specific analysis using cocktail
probes for high-risk (HR) and low-risk (LR) HPVs before
individual typing was performed. The HR cocktail probe consisted
of oligoprobes for HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66 and 68; the LR HPV probe consisted of oligoprobes for HPV6,
11, 26, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 70, 71, 72, 73, 81, 82
(MM4 and IS39 subtype), 83, 84 and CP6108. Types 73, 82, 26 and
53 were classified as HR (Mun ˜oz et al, 2003). During follow-up,
GP5þ/GP6þ PCR reverse line blot (PCR-RLB) analysis was
validated and used to type the 37 different HPV types detected by
PCR-EIA (van den Brule et al, 2002). In this validation process,
some samples from our cohort were tested using both techniques
and 96% agreement was observed between the PCR-RLB analysis
and the PCR-EIA assay. Specimens from the first four visits were
typed with PCR-EIA and those from subsequent visits were typed
with PCR-RLB. PCR-EIA was used to assess viral load in all visits.
This is a semiquantitative method based on the linear relationship
between the amount of DNA and the optical density (OD) in the
range of 10–10
6 genome equivalents (Jacobs et al, 1997).
Pap smears were read by a cytotechnologist and classified as
normal, atypical cells, HPV, mild, moderate and severe dysplasia,
cancer in situ and invasive cancer. All abnormal smears as well as a
10% sample of normal smears were reviewed by two expert
cytopathologists who re-classified the cytological diagnosis using
the Bethesda system as normal, atypical squamous cells of
undetermined significance, atypical glandular cells and LSIL or
HSIL (Luff, 1992). The same pathologists read the biopsies and
classified them as normal, cervicitis, cervical intraepithelial
neoplasia (CIN) grade 1, 2, 3, carcinoma in situ or invasive
cervical cancer.
Statistical analysis
The outcomes of interest for this analysis were clearance, duration
of incident type-specific HPV infections and incidence of CIN2/3
among women with normal cytology at enrolment. An incident
type-specific HPV infection was defined as the first positive type-
specific result after a negative result for the same HPV type.
Correspondingly, type-specific HPV clearance was defined as the
first negative PCR result after an incident infection. Duration of an
HPV incident infection was defined as the elapsed time from the
date of infection to the date of clearance, assuming both events
occurred at the mid point between consecutive visits with different
HPV status (i.e. negative to positive or positive to negative).
Because women could have one or more HPV infections during
follow-up, HPV type-specific infections, instead of individuals,
were the unit of analysis. HPV infections were categorised using
phylogenetic (de Villiers et al, 2004) and epidemiological
classifications (Mun ˜oz et al, 2003) in six groups as follows:
HPV16, HPV18, a-9 HPV types other than HPV16 (i.e. HPV31, 33,
35, 52, 58, 67), a-7 HPV types other than HPV18 (i.e. HPV39, 45,
68, 70), other HPV-HR types and LR HPV types.
In the analysis of clearance and duration of infection, we
censored women lost to follow-up after an incident infection and
those with a gap longer than 36 months between consecutive visits
because the most HPV infections clear within this time (Insinga,
2007). Also, women were censored if CIN2/3 was diagnosed.
Cox regression was used to evaluate factors potentially
associated with clearance, including viral load, co-infection, age
at infection, previous infection during follow-up, sexual behaviour,
parity and tobacco use. Viral load was included in the analysis as
the maximum viral load attained during an incident infection
for each defined viral group. Because there is no consensus on
reference values of ODs to classify viral load, they were categorised
in quintiles. The Kaplan–Meier method was used to estimate the
median duration of infection for most HPV types and for each of
the previously defined viral groups. Infections were considered
persistent if duration was above the median.
End points of interest for the CIN2/3 analysis included histology
confirmed CIN2 (9), CIN3 or carcinoma in situ (14), invasive
carcinoma (3) and cases of HSIL without histology confirmation
(6). The latter group was included because of the high specificity of
Pap smear and the low sensitivity of one colposcopically directed
biopsy. A recent report indicates that one colposcopically directed
biopsy misses at least one-third of CIN3þ (Gage et al, 2006).
To evaluate the association of our proposed definition of
persistent infection with the risk of CIN2/3 development we
carried out a Cox regression analysis adjusting for relevant
cofactors of HPV infection (i.e. age, parity, OC use, smoking
status and co-infection). Alternatively, we also used a longitudinal
approach grouping all possible triplets of consecutive visits by
individual to compare the results of the new approach with those
obtained using the traditional definition of persistence (ie two
consecutive positive visits) (Zeger and Liang, 1986). Specifically,
HPV type-specific status was assessed at the first two visits of every
triplet and classified as: (1) negative at both, (2) positive at either
or (3) positive at both visits. Women should have normal cytology
at the first visit of the triplet and lesion progression was assessed in
the third. Here the time lag between visits was not restricted and
logistic regression analysis was carried out using generalised
estimating equations to account for the correlation between
triplets of visits contributed by the same individual (Zeger and
Liang, 1986). In both approaches, we considered incident and
prevalent HPV infections and we adjusted for the same HPV
cofactors.
RESULTS
Of the 2139 women who agreed to participate in the cohort study,
261 had only one visit during follow-up and 150 had abnormal
cytology at baseline leaving 1728 (80%) women eligible for this
analysis (154 included based on data from the second visit). This
group represented 12526 follow-up visits with cervical scrapes
tested for HPV DNA.
The prevalence of HPV infection at baseline was 13.4% (224).
During follow-up, 253 and 209 women HPV DNA negative at
baseline developed single and multiple incident HPV type
infections, respectively. In addition, 110 women who were
HPV DNA positive at baseline developed incident infections
(i.e. infections with a different HPV type) during follow-up.
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HPV Type HPV16 SP 9 other than 16 HPV18 SP 7 other than 18 Other high-risk HPV Low-risk HPV
Women with incident
infections 124 176 55 137 164 216
Incident infection
excluded from analysis 8 13 7 6 13 17
No. of
women
No. of
events HR (95% CI)
No. of
women
No. of
events HR (95% CI)
No. of
women
No. of
events HR (95% CI)
No. of
women
No. of
events HR (95% CI)
No. of
women
No. of
events HR (95% CI)
No. of
women
No. of
events HR (95% CI)
Co-infection
No 63 51 1 84 69 1 17 15 1 56 49 1 78 62 1 82 67 1
Yes 53 45 0.98 (0.62–1.55) 79 67 0.83 (0.56–1.22) 31 24 0.50 (0.22–1.15) 75 62 1.04 (0.69–1.56) 73 57 1.01 (0.68–1.50) 117 89 0.87 (0.62–1.21)
Previous infection by other
HPV type
No 82 71 1 117 101 1.00 27 22 1 82 74 1 96 82 1 128 109 1
Yes 34 25 1.07 (0.61–1.88) 46 35 0.95 (0.62–1.45) 21 17 1.24 (0.52–2.97) 49 37 0.98 (0.63–1.54) 55 37 0.71 (0.46–1.11) 71 47 0.71 (0.49–1.03)
Viral load (quintile)
I lowest 22 19 1 33 30 1 7 5 1 25 23 1 32 25 1 77 63 1
II 24 21 0.56 (0.27–1.16) 32 29 0.74 (0.42–1.29) 11 11 0.84 (0.20–3.43) 29 28 0.62 (0.35–1.11) 28 25 0.97 (0.52–1.79) 47 40 0.86 (0.56–1.30)
III 31 27 0.29 (0.14–0.58) 32 27 0.56 (0.32–0.98) 9 9 0.60 (0.11–3.27) 29 24 0.47 (0.25–0.90) 30 23 0.78 (0.42–1.45) 27 19 0.51 (0.29–0.89)
IV 19 15 0.20 (0.09–0.47) 32 27 0.43 (0.24–0.77) 11 9 0.52 (0.09–2.90) 24 21 0.30 (0.15–0.58) 28 26 0.61 (0.33–1.124) 17 14 0.39 (0.21–0.72)
V 20 14 0.19 (0.09–0.42) 34 23 0.32 (0.17–0.60) 10 5 0.05 (0.01–0.29) 24 15 0.20 (0.10–0.42) 33 20 0.28 (0.14–0.58) 31 20 0.31 (0.18–0.55)
Age (years)
o30 41 31 1 67 54 1 15 12 1 42 36 1 61 48 1 61 50 1
X30 75 65 1.03 (0.53–1.99) 96 82 0.87 (0.53–1.42) 33 27 0.97 (0.32–2.94) 89 75 1.29 (0.69–2.39) 90 71 1.71 (1.01–2.90) 138 106 0.79 (0.49–1.27)
Parity
0–1 37 28 1 58 49 1 3 3 1 41 35 1 59 47 1 66 51 1
2–3 60 51 1.15 (0.60–2.18 79 64 1.38 (0.86–2.20) 28 22 0.45 (0.06–3.54) 65 59 1.61 (0.90–2.89) 64 54 1.25 (0.786–1.98) 100 77 1.20 (0.79–1.82)
43 18 16 0.99 (0.43–2.28 26 23 1.28 (0.68–2.42) 17 14 0.31 (0.02–3.99) 24 16 1.20 (0.55–2.59) 28 18 0.67 (0.35–1.31) 33 28 1.13 (0.60–2.13)
Oral contraceptives
Never 63 53 1 90 78 1 23 17 1 72 60 1 78 58 1 103 83 1
Ever 53 43 1.03 (0.65–1.64) 73 58 0.71 (0.48–1.05) 25 22 1.03 (0.40–2.63) 59 51 0.99 (0.64–1.54) 73 61 0.65 (0.42–0.99) 96 73 0.90 (0.64–1.25)
Intrauterine device
Never 47 35 1 57 50 1 18 15 1 53 43 1 63 54 1 89 69 1
Ever 69 61 0.99 (0.60–1.63) 106 86 0.93 (0.61–1.40) 30 24 2.37 (0.98–5.71) 78 68 1.04 (0.66–1.63) 88 65 0.79 (0.52–1.18) 110 87 1.17 (0.81–1.67)
New sex partners in past
6 months
No 105 86 1 142 121 1.00 45 36 1 116 98 1 133 105 1 183 142 1
Yes 11 10 0.36 (0.08–1.58) 20 14 0.67 (0.36–1.26) 3 3 0.49 (0.11–2.21) 14 12 0.64 (0.26–1.58) 18 14 0.74 (0.38–1.45) 14 12 1.16 (0.57–2.36)
Age at first intercourse
o17 34 24 1 63 49 1 15 11 1 39 30 1 61 47 1 61 48 1
17–21 62 56 1.43 (0.74–2.77) 79 70 1.22 (0.81–1.84) 20 16 1.15 (0.40–3.23) 64 56 0.73 (0.42–1.26) 68 52 0.89 (0.56–1.40) 97 74 1.06 (0.68–1.64)
X22 19 15 1.18 (0.48–2.92) 21 17 1.77 (0.93–3.38) 13 12 1.34 (0.32–5.54) 27 24 0.61 (0.28–1.32) 22 20 0.84 (0.43–1.65) 41 34 1.30 (0.74–2.30)
Smoking
Never 73 62 1 110 91 1.00 33 26 1 92 76 1 96 76 1 136 107 1
Ever 43 34 0.69 (0.43–1.10 53 45 1.36 (0.91–2.05) 15 13 0.57 (0.23–1.44) 39 35 0.75 (0.47–1.20) 55 43 0.99 (0.67–1.48) 63 49 0.84 (0.56–1.25)
HPV¼human papillomavirus.
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yThus, a total of 572 women developed 872 type-specific incident
HPV infections during follow-up; 64 infections were excluded from
the analysis because the interval between consecutive visits was
longer than 36 months or got no further visits after the infection
(Table 1). Median interval between visits was 6.6 months
(interquartile range, IQR: 6.0–9.2), median duration of follow-up
for clearance analysis was 6.4 years (IQR: 3.7–8.5 years) and
median duration of total follow-up was 8.9 years (IQR: 6.3–9.4
years).
Maximum viral load attained during follow-up ranged from 0.18
to 4.07 OD. The IQR was similar among HR HPV types groups,
with a median of 1.8–2.0 OD, whereas the median was lower in the
LR HPV group (0.8 OD).
Cox regression analysis including all relevant cofactors for HPV
infection shows that clearance of incident infections by HPV types
is inversely associated with viral load (Table 1). The likelihood of
clearance was significantly reduced for infections with higher viral
load for all HPV groups (P-value for trend o0.001). With the
exception of use of an intrauterine device that doubled the chance
of clearance for HPV18 infections and age older than 30 years that
increased 70% the probability of clearance of ‘other HR HPV’,
none of the factors affected the likelihood of clearance. For all HPV
groups, except HPV16, clearance was similar in women under 30
years of age and in women aged 30 years or older. Although no
apparent differences in the probability of clearance between HPV
groups were observed (Figure 1), difference of clearance with age
in HPV16 infection (log-rank test Po0.01) was lost in the adjusted
analysis (Table 1).
Median duration of HPV incident infection seemed higher for
HR HPV types than for LR types (Figure 1), but confidence
intervals (CI) between types and between age groups had
substantial overlap, except for HPV16 for which younger women
had significantly longer persistence of infection. Although virtually
all infections with lowest viral loads were cleared by the second
year of follow-up, those with viral load in the highest quintile
persisted longer. However, after 5 years of follow-up most of the
infections have cleared (Figure 2).
Among women with normal cytology at baseline, 32 CIN2/3/
HSIL incident cases were diagnosed during follow-up (0.23 per 100
person-years; 95% CI 0.16–0.33). Incident HPV infections
occurring in women under age 30 carry a risk of CIN2/3 similar
to that of incident infections occurring later (o30: 0.025 per 100
person-years, 95% CI 0.015–0.042; X30: 0.023, 95% CI 0.014–
0.037). Most cases (n¼25) were associated with HPV16 and other
types from the a-9 group. For HPV16, only those infections that
lasted more than the median duration were associated with an
increased risk of CIN2/3/HSIL, compared with no HPV16
infection, and this occurred in both age strata (o30 and X30).
The two cases of CIN2/3 that occurred after infection of short
duration were diagnosed in the second visit.
For a-9 other than 16, infections lasting less than the median, as
well as those lasting more, were associated with an increased risk
of CIN2/3/HSIL (Table 2); this also applied in the analysis based on
triplets. Risk of CIN2/3 was higher for HR HPV types at two
consecutive visits than for infections positive at only one visit; no
significant association was observed for LR types. For HPV16 the
increased risk was particularly marked when women were positive
in two consecutive visits and it was also increased, but not
significantly, when women were positive in only one visit. For a-9
other than 16, an increased risk was observed for women positive
at one of the two consecutive visits, as well as at the two
consecutive visits. Median time between the first two visits was
similar for all HPV group infections (7.5 months) (Table 3).
DISCUSSION
Understanding the natural history of HPV infection and the
resulting cervical lesions requires long-term follow-up studies in
which cervical cells and risk factor information are collected at
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LR HPV types Other HR HPV typed
Age  median (95% CI)
<30: 12.4 (8.6–15.9) 
           n=61  
 30+: 10.9 (9.0–13.1) 
          n=138
Age  median (95% CI)
<30: 15.6  (11.3–18.3)
            n=61 
  30+: 11.4  ( 9.0–14.7) 
             n=90 
   Age  median (95% CI)
    <30: 16.6 (8.9–19.5) 
                n=41 
    30+: 9.5 (7.8–12.9 ) 
                n=75 
  Age  median (95% CI)
  <30: 12.44 (7.5–14.5) 
           n=15 
   30+: 11.73 (7.8–18.1) 
          n=33 
Age  median (95% CI)
<30: 14.5 (11.3–16.9) 
          n=67 
30+: 13.3 (11.0–14.6) 
           n=96  
        Age  median (95% CI)
<30: 14.7 (11.3–17.7) 
                    n=42    
          30+: 12.8  (9.7–15.2) 
                 n=89 
Figure 1 Cumulative probability of clearance of incident HPV infection, by viral group and age group (under 30 years and 30 years and over), in women
with normal cytology at baseline. Number of infections (n) with point estimates and 95% CI of median duration of infection by age group are reported.
HPV16 persisted significantly longer in women under 30 years of age than older women (Po0.01, log-rank test).
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cervical lesions. Most studies (Ho et al, 1998; Moscicki et al, 2001;
Woodman et al, 2001; Brown et al, 2005; Winer et al, 2005) include
young women from populations at LR for cervical cancer and do
not discriminate incident from prevalent infections in the analysis.
Our study was conducted in a population at HR of cervical cancer,
including young and older women, where incident HPV infections
were considered separately. A high prevalence and incidence of
cervical HPV infection has been reported in this cohort (Molano
et al, 2002a; Mun ˜oz et al, 2004).
Our results show that viral load is the main determinant of
clearance and that clearance of incident infection occurs, in almost
all cases, at 5 years showing no difference between viral types. This
is remarkable considering possible misclassification in viral load
measurements due to the semiquantitative method used in this
cohort study. This method has shown moderate correlation with
the real-time PCR assays that are considered more accurate
(Hesselink et al, 2005). The importance of viral load as a
determinant of persistence supports recent observations suggest-
ing that GP5þ/GP6þ viral load is a good parameter to
distinguish those HR HPV infections that will progress to CIN3þ
from those that will not (Snijders et al, 2006; Gravitt et al, 2007).
Our results agree with other longitudinal studies using semiquan-
titative and quantitative PCR assays that show that high viral load
is associated with an increased risk for HSIL or CIN2/3 (Ylitalo
et al, 2000; van Duin et al, 2002; Schlecht et al, 2003; Dalstein et al,
2003; Monnier-Benoit et al, 2006). However, other studies using
hybrid Capture 2 viral load measurement for a pool of 13
carcinogenic HPV types have yielded negative results (Lorincz
et al, 2002; Castle et al, 2004). There are at least two possible
explanations for the discordant results: first, comparison between
studies is difficult because results are not given in absolute
measurements; second, studies using hybrid Capture 2 viral load
measurement provide an additive measurement of 13 types,
whereas those giving positive results provide measurement for
individual types and most have focused on HPV16. Although
quantitative PCR techniques provide information on the amount
of viral particles in each cell and correct for differences in
amplification efficiency between samples, they cannot be used in
large studies because they are laborious, expensive and have been
developed only for a few HPV types (HPV16, 18, 31, 33, 45 and 58).
In contrast, semiquantitative assays, though they analyse the
number of viral copies by scrapes and not by cells and perform less
Table 2 Risk and HR of high-grade cervical dysplasia (CIN2/3/HSIL) by
duration of HPV infection
Viral type
Median
duration
(month) Cases
a
Rate
(per 100) HR* (95% CI)
HPV16 Negative 17 0.15 1
o10.83 2 0.49 3.59 (0.82–15.70)
X10.83 12 2.24 19.51 (9.07–42.00)
HPV a-9 SP but 16 Negative 20 0.18 1
o13.79 6 0.94 5.38 (2.58–11.22)
X13.79 5 0.77 3.12 (1.19–8.18)
aOne case excluded as duration of infection could not be computed. *Adjusted for
age, parity, smoking status, oral contraceptive use, and HPV co-infection. HPV¼
human papillomavirus.
Table 3 Risk of high-grade cervical dysplasia (CIN2/3/HSIL) by number
of HPV-positive visits
Triplets
a
HPV status Cases Control Adjusted OR
b (95% CI)
HPV16
Negative at both 6 8.121 1
Positive at either 2 229 6.13 (0.56–66.55)
Positive at both 7 75 193.46 (46.49–805.09)
a-9 other HPV16
Negative at both 10 8.014 1
Positive at either 2 334 13.51 (2.39–76.28)
Positive at both 2 95 48.31 (7.75–301.02)
Any high-risk HPV
Negative at both 1 7.241 1
Positive at either 5 915 23.43 (2.24–244.70)
Positive at both 10 351 168.66 (17.84–1594.27)
Any low-risk HPV
Negative at both 12 7.876 1
Positive at either 2 454 0.62 (0.06–6.11)
Positive at both 1 111 2.29 (0.26–20.16)
aFrom 1539 clusters (women).
bAdjusting for parity, age, oral contraceptives and
smoking, co-infection and clustering. HPV¼human papillomavirus.
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Figure 2 Cumulative probability of clearance of incident HPV infections
by viral load (lower and fifth quintile) and viral group, in women with
normal cytology at baseline. Viral load was estimated from the optical
density and values categorised in quintiles.
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adequately in high viral load ranges that are clinically relevant
because they are associated with an increased risk of disease.
However, one limitation of our findings is that we have used the
maximum viral load attained during an incident infection and little
is known on the dynamics of viral load during the course of an
incident infection.
The lack of differences in persistence by viral type is at odds
with the results obtained in a previous analysis of the same
population where only prevalent HPV infections were considered
(Molano et al, 2003). HPV16 had a significantly lower clearance
than LR types and HR types other than a-9 species, and HPV types
related to HPV16 had intermediate clearance rates. Such
differences might be due to our restricting the analysis to incident
infections in women with normal cytology at baseline and
conducting a separate analysis by viral group instead of comparing
between them. This approach gave us more observations to analyse
and a straightforward interpretation of results as no viral type was
considered as reference value.
An unexpected result was the lack of difference in the
probability of clearance in women by age (under and over 30),
contrary to a report from Guanacaste, Costa Rica that persistence
increases with age (Castle et al, 2005). However, our results
are in agreement with the lack of association between age and
duration of infection recently reported from a cohort study
similar to ours in Brazil (Trottier et al, 2008). Differences in study
design (including the definition of persistence and inclusion of
prevalent and incident HPV infections) and in statistical analysis
may explain the discrepancies. In the Guanacaste study, persis-
tence was defined as HPV DNA positivity at enrolment and at a
single follow-up visit 5–7 years after enrolment, and survival
analyses were not used.
We are proposing a new definition of persistence based on
duration of incident infection, that is persistent infections are
those lasting more than the median duration.
We believe that this definition is more informative than the
traditional based on two consecutive HPV-positive tests that can
be separated by irregular time intervals.
The risk pattern of CIN2/3/HSIL associated with the two
definitions of persistence was remarkably similar. This is not
surprising considering that our follow-up visits were separated by
regular intervals of about 7 months. When persistence was defined
as HPV DNA positivity at two consecutive visits, the risk was
higher than when HPV DNA positivity was detected only at one of
the two consecutive visits.
These results accord with those obtained in a recent meta-analysis
in which persistence defined as HPV positivity at two or more time
points was associated with an increased risk of CIN2/3 in most
studies. However in this meta-analysis there was notable hetero-
geneity among the few studies that provided sufficient data to obtain
HPV16 and 18 type-specific associations (Koshiol et al,2 0 0 8 ) .
Our finding of an increased risk for CIN2/3 associated with HPV
positivity at only one follow-up visit for a-9 types other than
HPV16 indicates that HPV infections of short duration may also
increase the risk of CIN2/3 lesions or that persistence is not
essential for progression to high-grade lesions.
Our results accord with recent reports that HPV type and
persistence are the main determinants of progression to CIN2/3. In
particular, repeat detection of HPV DNA16 is associated with
extremely high cumulative risk of subsequent CIN3þ diagnosis,
exceeding 30% in some cohorts (Schiffman et al, 2007; Rodriguez
et al, 2008).
Our study has several strengths, including the relatively large
sample size, the broad age range covered, the low proportion of
refusals, the long follow-up period, the short interval between
follow-up visits (median 6.6 months), the comprehensive informa-
tion collected at baseline and during follow-up on risk factors, and
the use of sensitive and well-validated PCR assays for the detection
of HPV DNA in a central laboratory. The main limitation of our
study is the relatively small number of CIN2/3 lesions detected,
which makes our risk estimates unstable.
In conclusion, in this cohort of Colombian women, viral load is
the most important determinant of HPV persistence, and persis-
tence of HPV16 infections carry a higher risk of CIN2/3. The
occurrence of CIN2/3 after non-persistent a-9 infections other than
HPV16 suggests that such lesions are early manifestations of HPV
infection and are more likely to regress. These observations have
important implications in forecasting the impact of prophylactic
HPV vaccines and screening programs using HPV tests.
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